- Home
- ALNY
as 03-25-2025 4:00pm EST
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 35.0B | IPO Year: | 2004 |
| Target Price: | $319.27 | AVG Volume (30 days): | 901.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 23 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $141.98 - $304.39 | Next Earning Date: | 05-01-2025 |
| Revenue: | $2,248,243,000 | Revenue Growth: | 22.97% |
| Revenue Growth (this year): | 31.04% | Revenue Growth (next year): | 23.56% |
Stock Insider Trading Activity of Alnylam Pharmaceuticals Inc. (ALNY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | ALNY | Director | Mar 24 '25 | Sell | $299.00 | 7,440 | $2,224,560.00 | 136 | |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Mar 21 '25 | Sell | $292.50 | 9,766 | $2,864,985.00 | 20,221 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Mar 3 '25 | Sell | $243.86 | 2,755 | $669,304.07 | 15,521 | |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Mar 3 '25 | Sell | $243.92 | 2,557 | $621,150.40 | 20,221 | |
| Tanguler Tolga | ALNY | EVP, Chief Commercial Officer | Mar 3 '25 | Sell | $244.82 | 471 | $114,820.42 | 28,011 | |
| Poulton Jeffrey V. | ALNY | EVP, Chief Financial Officer | Mar 3 '25 | Sell | $245.33 | 1,264 | $308,140.61 | 47,752 | |
| Fitzgerald Kevin Joseph | ALNY | CSO & EVP, Head of Research | Feb 28 '25 | Sell | $240.70 | 496 | $119,877.91 | 15,521 | |
| Greenstreet Yvonne | ALNY | Chief Executive Officer | Feb 27 '25 | Sell | $240.70 | 2,900 | $700,893.68 | 84,761 | |
| Garg Pushkal | ALNY | CMO & EVP Dev & Med Affairs | Feb 27 '25 | Sell | $240.70 | 935 | $225,976.83 | 20,221 | |
| Tanguler Tolga | ALNY | EVP, Chief Commercial Officer | Feb 27 '25 | Sell | $240.70 | 513 | $123,983.10 | 28,011 |
Latest Alnylam Pharmaceuticals Inc. News
ALNY Breaking Stock News: Dive into ALNY Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
MT Newswires
2 days ago
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280
Simply Wall St.
3 days ago
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision
TipRanks
4 days ago
Alnylam price target raised to $338 from $300 at Scotiabank
Morningstar Research
5 days ago
Analyst Report: Alnylam Pharmaceuticals, Inc.
Investor's Business Daily
5 days ago
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
MT Newswires
5 days ago
Sector Update: Health Care Stocks Retreat Late Afternoon
Pharmaceutical Technology
5 days ago
Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug
Compare ALNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALNY Alnylam Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.